Reta Glp 3 (Retatrutide) 20mg Research Peptide
Retatrutide is a GLP-1/GIP/glucagon triple receptor agonist peptide developed by Eli Lilly. This 20mg vial provides research-grade retatrutide at ≥99% purity, HPLC and MS/MS verified per batch. Suitable for extended in vitro research protocols requiring larger quantities.
Research Background
Published Phase 2 data (NEJM, 2023) showed retatrutide achieving up to 24.2% mean weight reduction at 48 weeks — exceeding outcomes seen with dual GLP-1/GIP agonists. The compound’s GCGR component raises basal energy expenditure and promotes hepatic fat clearance, making it a subject of active NAFLD/MASH research. Phase 3 trials ongoing as of 2026.
For a full overview of retatrutide’s mechanism, clinical trial data, dosage reference, and comparison with tirzepatide, see our Retatrutide Peptide Research Guide. Also available in 10mg, 30mg, and 40mg vials.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 20mg per vial
- Storage: −20°C, protected from light
- CAS Number: 2381272-12-2
Certificate of Analysis
Third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
